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Tailored Immune Responses: Novel Effector Helper T Cell
Subsets in Protective Immunity
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Shaun R. McColl*
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Abstract: Differentiation of naı¨ve CD4+ cells into
functionally distinct effector helper T cell subsets,
characterised by distinct ‘‘cytokine signatures,’’ is a
cardinal strategy employed by the mammalian immune
system to efficiently deal with the rapidly evolving array of
pathogenic microorganisms encountered by the host.
Since the TH1/TH2 paradigm was first described by
Mosmann and Coffman, research in the field of helper T
cell biology has grown exponentially with seven func-
tionally unique subsets having now been described. In
this review, recent insights into the molecular mecha-
nisms that govern differentiation and function of effector
helper T cell subsets will be discussed in the context of
microbial infections, with a focus on how these different
helper T cell subsets orchestrate immune responses
tailored to combat the nature of the pathogenic threat
encountered.
Introduction
Bidirectional intercellular communication between innate and
adaptive immune systems is crucial for success of immunity to
microbial infection. The activation and fate of clonally selected
cells of the adaptive immune system is strongly influenced by
innate effector cells, and orchestration of adaptive responses to
pathogenic microorganisms requires synergistic collaboration with
the innate immune system to efficiently resolve infection. Via
production of diverse pleiotropic cytokines, effector CD4+ T
helper (TH) cells function to direct efficient immune reactions by
dictating the actions of both innate and adaptive arms of the
immune system. Through their ability to coordinate innate/
adaptive effector cell activity, TH cells directly and/or indirectly
influence almost every aspect of an immune response: they provide
signals to help B cells undergo class switch recombination (CSR),
affinity maturation and differentiation, perpetuate CD8+ T cell
responses, regulate the recruitment and function of innate effector
cells, and contract responses to resolve and/or adjust the
magnitude of inflammation.
Pathogen-specific CD4+ T cells coordinate immune responses
by differentiating into discrete subsets of effector TH cells defined
by production of distinct cytokine ‘‘signatures’’. The specific
differentiated state of effector TH subsets is attributed to their
expression of subset-specific transcription factors that programme
subset-specific transcriptomes, whilst concomitantly suppressing
alternative fates the precursor could have assumed [1]. Induction
of these transcriptional programmes is predominantly determined
by innate-immune-derived cytokines present during MHC-II-
restricted T cell receptor (TCR)-mediated activation released into
the ‘‘immunological synapse’’ by antigen-presenting cells, partic-
ularly by DCs (examples shown in Figure 1). DCs are themselves
instructed to produce cytokines following detection of specific
pathogen-associated molecular patterns (PAMPs) on foreign
microbes through pattern recognition receptors (PRRs) during
pathogen encounter in the periphery [2]. Thus, important
information regarding the nature of the specific pathogens can
be conveyed to developing effector helper T cells that subsequently
differentiate into an effector programme equipped with a
particular cytokine-secreting repertoire, thereby eliciting a path-
ogen-tailored immune response.
These views of helper T cell differentiation and function were
first introduced by Mosmann and Coffman in 1986, who
demonstrated that T cell clones were divisible into two subsets,
termed TH1 and TH2, based on their mutually exclusive
production of interferon (IFN)-c or interleukin (IL)-4, -5, and -
13, respectively [3]. This subdivision was of major significance as
IFN-c-producing TH1 cells were subsequently shown to be critical
in host defences against intracellular pathogens by activating cell-
mediated immunity, whilst TH2-driven responses were essential
for efficient humoral responses against extracellular microbes. The
TH1/TH2 paradigm served as a useful conceptual construct for
understanding how TH cells controlled different arms of the
immune system, and dysregulation of TH1/TH2 responses has
since been implicated in the pathogenesis of many immune-related
disorders such as autoimmune and allergic disease. Development
of techniques such as multi-parameter flow cytometry and
engineering of fate-mapping cytokine reporter mice has recently
facilitated major progress in TH cell biology, with seven
functionally unique TH subsets now described. These comprise
TH1, TH2, TH17, follicular helper T cells (TFH), inducible T
regulatory cells (iTreg), and the most recently described and least
well-characterised subsets, TH9 and TH22 cells, each of which is
produced upon antigen presentation in the presence of specific
cytokines or sets of cytokines (Figure 1). In this review, recent
insights into the mechanisms that govern differentiation, migra-
tion, and function of effector TH cells will be discussed in the
context of microbial infection, focussing on the contribution of
Citation: Kara EE, Comerford I, Fenix KA, Bastow CR, Gregor CE, et al. (2014) Tailored
Immune Responses: Novel Effector Helper T Cell Subsets in Protective
Immunity. PLoS Pathog 10(2): e1003905. doi:10.1371/journal.ppat.1003905
Editor: Tom C. Hobman, University of Alberta, Canada
Published February 20, 2014
Copyright:  2014 Kara et al. This is an open-access article distributed under
the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
Funding: This work was supported by the NH&MRC (Project grant APP1009002,
http://www.nhmrc.gov.au). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests
exist.
* E-mail: shaun.mccoll@adelaide.edu.au
PLOS Pathogens | www.plospathogens.org 1 February 2014 | Volume 10 | Issue 2 | e1003905
emerging subsets of effector helper T cells, with less emphasis on
TH1 and TH2 subsets, whose function has been well-established
and is described elsewhere [4]. The function of Tregs in protective
immunity will also not be discussed in this review as this has been
the subject of recent comprehensive review elsewhere [5].
T Helper 1 (TH1) and T Helper 2 (TH2)
TH1 differentiation from naı¨ve precursors is initiated by signal
transducer and activator of transcription (STAT)-1 activation
downstream of type 1 interferon, IFN-c and IL-27 signalling,
which induces expression of the TH1-specific master transcription
factor T-bet [6–9]. This process enables activated CD4+ T cell
responsiveness to DC-derived IL-12 via T-bet-mediated induction
of the high-affinity IL-12 receptor beta 2 chain on the cell surface
[10–12]. IL-12 signalling through STAT4, together with T-bet,
directly transactivates the Ifng gene, which further promotes TH1
differentiation via STAT1 activation in an autoregulatory
feedback loop [13–15]. T-bet also drives expression of the
chemokine receptor CXCR3, which facilitates TH1 migration to
inflamed sites of pathogen encounter where CXCL9, CXCL10,
and/or CXCL11 are produced (Figure 1) [12,15–17]. TH1 cells
orchestrate the cell-mediated cytotoxic response against intracel-
lular pathogens principally via provision of IFNc to enhance
macrophage activation and promote activation of antigen-specific
cytotoxic T lymphocytes (CTLs). Classical infections controlled or
cleared by effective TH1 responses include intracellular bacteria
such as Listeria monocytogenes, Salmonella species, and Mycobacterium
tuberculosis, intracellular parasites such as Leishmania donovani, and a
number of viral pathogens [18–25]. In addition, TH1-derived
production of the pro-inflammatory cytokine IL-21 has also been
shown to be a key regulator of the long-term maintenance and
functionality of antigen-specific CTLs important for protection
against both acute and chronic infection with lymphocytic
choriomeningitis virus (LCMV) [26–28].
Despite the appreciation of the existence of the TH2 subset for
more than 25 years, the molecular mechanisms that govern TH2
differentiation remain controversial. Early reports demonstrated
that the TH2 differentiation programme is set up via STAT6
activation downstream of IL-4 signalling, directly transactivating
the TH2-lineage-specific transcription factor GATA-3 that in turn
induces expression of the TH2-specific cytokine genes Il4, Il5, and
Il13 [29–36]. However, recent studies suggest that TH2 cell
induction may be far more complex than originally described, with
reports that TH2 differentiation can occur independently of the
STAT6/IL-4 axis [37] and may require additional cytokines
including IL-2, IL-25, IL-33, and thymic stromal lymphopoietin
(TSLP) (reviewed in [4,38]). Nevertheless, production of IL-4, -5,
and -13 by TH2 cells plays important roles in the activation and
recruitment of basophils, induction of eosinophilia, regulation of
antibody-dependent cell-mediated cytotoxicity (ADCC) mecha-
nisms, and, by acting on resident cells at sites of inflammation,
creates a hostile environment that favours extracellular microbial
expulsion [4]. TH2 cells express the chemokine receptors CCR3,
CCR4, and CCR8, and thus migrate to sites expressing their
ligands in response to infection (Figure 1) [39,40]. Effective TH2
responses are required for host defence against extracellular
parasites such as Schistosoma mansoni or Trichuris muris [41–44].
The subdivision of T cells into TH1 and TH2 subsets has utility
in understanding how the adaptive immune system tailors
responsiveness to different types of pathogens by directing the
activation of distinct immune components. Clearly however, the
TH1 and TH2 subdivision is an oversimplification as the
substantial pathogen diversity warrants more than two broad
types of immune response. Therefore, it is perhaps surprising that
it was only relatively recently that the TH1 and TH2 paradigm has
Figure 1. Currently known TH cell subsets. Polarising cytokines encountered during TH cell differentiation drive the expression of subset-specific
transcription factors, which imprint subset-specific transcriptomes in the TH cell. These transcription factors define the effector function and
migratory capability of the TH cell via regulation of subset-specific cytokines and chemokine receptors.
doi:10.1371/journal.ppat.1003905.g001
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been expanded to definitively include additional subsets of T cells
and the role of these subsets in responses to distinct microbial
challenges has been interrogated. In the remainder of this review,
these emerging subsets of T cells and their role in protective
immunity will be described.
T Helper 17 (TH17)
It was not until 2005 that a third major population of effector
TH cells was described on the basis of the observation that
peripheral CD4+ T cells could differentiate into a distinct lineage
in a GATA-3– and T-bet-independent fashion [45,46]. Early
reports suggested that these cells did not produce molecules
commonly associated with TH1 or TH2 subsets but characteris-
tically expressed the highly pro-inflammatory cytokines IL-17A
and IL-17F, and were subsequently designated TH17. However,
later studies have demonstrated that subsets of TH17 cells can
produce IFN-c, IL-4, or IL-13 under certain circumstances [47–
50], although the function of TH17-derived IFN-c, IL-4, or IL-13
has yet to be explored in infectious models. TH17 differentiation
requires IL-6 and is also promoted by the otherwise immuno-
suppressive cytokine TGF-b1 (Figure 1) [51–53]. Signal trans-
duction downstream of these cytokines, including STAT3
activation downstream of the IL-6 receptor, induces expression
of the TH17-lineage-specific transcription factor RORct, which
directly transcribes the TH17-lineage-specific cytokines Il17a and
Il17f (Figure 1) [54–57]. IL-6-mediated induction of IL-21 during
TH17 cell differentiation is reported to reinforce TH17-lineage
commitment via STAT3 activation downstream of the IL-21
receptor in an autocrine manner [53,58,59]. It has also been
reported that autocrine TGF-b1 promotes TH17 cell differenti-
ation in vivo [60]. Whilst addition of IL-6 and TGF-b1 into naı¨ve
CD4+ T cell cultures does indeed drive TH17 cell differentiation,
the in vivo requirements of TH17 cell differentiation are far more
complex than these in vitro conditions. Recent reports suggest that
TH17 cell differentiation can be induced independent of TGF-b1
signalling when driven by the inflammatory cytokines IL-6, IL-
1b, and IL-23 [61]. TH17 cells induced independently of TGF-b1
(termed TH17(23), owing to their requirement for IL-23) appear
to possess more inflammatory characteristics than conventional
TGF-b1-driven TH17 cells (TH17(b)). Furthermore, it has also
recently been shown that IL-6 and TGF-b3 drive differentiation
of TH17 cells that are functionally and molecularly distinct to the
conventional TH17(b) cell [62]. Thus, it is likely that TH17 cells
in any given response may comprise a heterogeneous population
of distinct types of TH17 cells that arise in discrete cytokine
microenvironments, possess distinct but similar transcriptomes,
and subsequently possess different cytokine-secreting repertoires
and functions. However, these hypotheses remain to be exten-
sively tested. Characteristically, TH17 cells express the chemokine
receptor CCR6 and their homing is thereby regulated by the
CCR6 ligand, CCL20, at sites of infection [63]. The near-
ubiquitous expression of the IL-17 receptor on non-haematopoi-
etic cells facilitates the broad physiological functions of TH17 cells
during inflammation. Through the induction of the inflammatory
chemotactic factors CXCL1, CXCL2, CXCL5, and CXCL8 at
sites of inflammation via production of IL-17A/F, IL-22, and
GM-CSF, TH17-mediated responses are dominated by the
inflammatory and phagocytic functions of neutrophils [64].
Other TH17-mediated functions include induction of antimicro-
bial peptides (including S100 proteins and b-defensins), promo-
tion of granulopoiesis via induction of G-CSF, and enhancement
of monocyte and neutrophil activation to promote their
phagocytic activity [64].
Whilst TH17 cells represent, in most cases, the major source of
adaptive IL-17 during microbial infection, IL-17 elicited from
non-TH cell sources can also be a determining factor in host
defence. Invariant natural killer T (iNKT) cells, natural killer (NK)
cells, cd-T cells, and type 3 innate lymphoid cells (ILC) (including
lymphoid tissue-inducer (LTi) cells) have all been shown to
produce protective innate-derived IL-17 in response to infection
[65–68]. The importance of IL-17 derived from non-TH17 cell
origins has recently been reviewed elsewhere [69,70].
Recent gene-knockout studies have demonstrated the vital
importance of IL-17-mediated inflammatory responses for host
defences at epithelial barriers, particularly against notoriously
persistent extracellular bacteria and fungi (Figure 2, panel A).
Seminal work by Ye et al. demonstrated the critical importance of
IL-17 for protective immunity in a murine model of extracellular
bacterial infection using Klebsiella pneumoniae in IL-17R-deficient
mice [71]. These mice were more susceptible to intranasal K.
pneumoniae infection relative to WT counterparts, which correlated
with significant delay in neutrophil recruitment into the alveolar
space and heightened dissemination of bacteria into the circulation
[71]. Numerous studies that followed confirmed the essential role
of IL-17 in host protection against K. pneumoniae [71–73]. Mice
infected with other extracellular bacteria including Citrobacter
rodentium [74,75], Bordetella pertussis [76,77], Porphyromonas gingivalis
[78,79], or Streptococcus pneumoniae [80,81], for example, also mount
protective IL-17 responses, and disruption of IL-17A or its
receptor leads to exacerbated bacterial burden or dissemination,
increased disease susceptibility resulting from defective induction
of CXC chemokines, and impaired neutrophil recruitment to sites
of bacterial inoculation. Mice with deficiencies in IL-23, a cytokine
axis critical for the stabilisation of the TH17 phenotype [82], also
display exacerbated pathology associated with numerous extracel-
lular bacterial infections. IL-23p19-deficient mice, akin to IL-17–
or IL-17R-deficient mice, also fail to effectively mount protective
IL-17 responses to C. rodentium [52] and K. pneumoniae [72]
infections. In the absence of these components of the TH17– and
IL-17-producing innate cell response, bacterial clearance is
impeded, leading to augmented bacterial dissemination and
disease susceptibility associated with reduced early IL-17-mediated
neutrophil infiltration. Importantly, administration of recombinant
IL-17 into IL-23-deficient infected mice restored neutrophilia at
sites of inoculation [72], demonstrating the critical importance of
the IL-23/IL-17 axis in host defence against various extracellular
bacterial infections. Whilst these studies strongly implicate a
protective role for the IL-23/IL-17 axis in protection against
extracellular infections at epithelial surfaces, the precise cellular
origin of IL-17 remains controversial. In the context of C. rodentium
infection, both an early innate and late adaptive source of IL-17 is
thought to be crucial to host protection. Interestingly, IL-17
responses early during C. rodentium infection were shown to be
elicited from a specialised subset of CD4+ T cells present within
the lamina propria (LP) [83]. Differentiation of these cells was
dependent on the innate immune sensor receptors NOD-1 and
NOD-2, which were shown to regulate intestinal DC-derived IL-6
and subsequent differentiation of these LP-resident ‘‘early’’ TH17
cells. Importantly, NOD-1/NOD-2 deficiency did not alter IL-
17A production during the late ‘‘adaptive’’ phase of infection
suggesting that these sensors specifically regulate early CD4+-T-
cell-derived IL-17. Thus, based on their rapid induction and
distinct dependency on NOD-1/NOD-2, these early TH17 cells
were termed innate TH17 (iTH17) cells. iTH17-derived early IL-17
is not restricted to C. rodentium infection as the same study
demonstrated that these cells also contribute to defence against S.
typhimurium, another attaching and effacing bacterium [83]. Other
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cells, including cd-T and ILC3 cells, have also been shown to
produce IL-17 following extracellular bacterial challenge [83–86].
Thus, it will be important to delineate the source of IL-17 in the
context of extracellular bacterial infections to fully understand the
function of TH17 cells in these settings. Experiments where IL-17
is specifically deleted in the T cell compartment will be required to
obtain this information.
The importance of IL-17-driven inflammation in the context of
antifungal host defence has also been established. In mice and
men, pathogen-specific TH17 responses have been shown to
confer protection against the dimorphic filamentous fungus
Candida albicans [87]. Within the memory CD4+ T cell pool of
healthy volunteers, Candida-specific TH cells are enriched within
the TH17 subset and significantly heightened numbers of IL-17-
producing cells in peripheral leukocytes of acute Candida-infected
patients have been documented compared to healthy controls
upon restimulation with Candida antigens [88]. Moreover, chronic
mucocutaneous candidiasis patients have diminished numbers of
IL-17A-producing cells within the peripheral leukocyte pool
compared with acutely infected patients and healthy controls
[89]. These data, and observations that patients with autosomal
dominant hyper-IgE syndrome, characterised by defects in TH17
differentiation due to mutations in the TH17-polarising transcrip-
tion factor STAT3 [90–92], are more susceptible to Candida and
other fungal infections, support an important role for the TH17
response in effective antifungal immunity [93]. More detailed
analyses of the functional role of IL-17 in fungal immunity have
come from murine models of experimental fungal infection. In line
with human studies, mice with a deficiency in IL-17A or its
receptor are more susceptible to experimental fungal infection.
Figure 2. Novel TH subsets in inflammation. (A) TH17 and TH22 cells have overlapping functions in the mouse. Via production of the
inflammatory mediators IL-17A, IL-17F, GMCSF (TH17), and IL-22 (TH22), these TH subsets mediate protective immunity against extracellular pathogens
intimately associated with mucosal barriers. (B) TH9-cell-derived IL-9 may play an important role in antiparasitic immunity via mediating mast cell
activation and mastocytosis, increasing the chemotactic potential of an inflammatory site via regulation of inflammatory chemokine production, and
promote basophil and eosinophil function.
doi:10.1371/journal.ppat.1003905.g002
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A role for the IL-17 axis in antifungal immunity in mice was first
described in 2004, in a study in which intravenous infection of IL-
17R-deficient mice with Candida led to decreased survival rates and
augmented fungal burden in the kidney [94]. In a model of
oropharyngeal candidiasis (known as ‘‘thrush’’), mice with
deletions in IL-23p19, IL-17RA, or IL-17RC developed exacer-
bated thrush lesions associated with augmented fungal burdens,
whilst mice deficient in TH1 effector cytokines IFN-c or TNF-a
were resistant to oral infection [95–97]. Critical requirements for
the IL-23/IL-17 axis in protective immunity have also been
described in murine models of dermal candidiasis [98]. Collec-
tively, these studies demonstrate that the IL-17 response is essential
for protective immunity against disseminated, skin, or mucosal
Candida infection. Whilst it was believed that TH17 cells represent
the major cellular source of protective IL-17 against Candida, a
recent study demonstrated that ILC3-derived IL-17 was the
critical source of this cytokine in an oropharyngeal candidiasis
infection model [67]. Immunity to oropharyngeal infection with
Candida was not altered in Rag-deficient or T-cell-deficient
animals, suggesting that TH17-cell-derived IL-17 was not an
important component of host defence. Antibody-mediated deple-
tion of all ILCs, as well as deletion of ILC3 cells using Rorc-
deficient mice, led to enhanced susceptibility to Candida infection,
implicating ILC3 cells as the crucial cellular source of protective
IL-17 in this model. Further investigation is required to determine
the contribution of innate and adaptive sources of IL-17 in other
models of primary Candida infection or other fungal pathogen
models where IL-17 has been shown to confer protection including
Cryptococcus neoformans [99], Aspergillus fumigatus [100], and Pneumo-
cystis carinii [101]. Taken together, recent data have suggested that
both TH17– and innate-cell-derived IL-17 play important roles in
the context of extracellular bacterial and fungal infections. It is
likely that innate IL-17 is crucial as the first line of defence whilst
the pathogen-specific TH17 cell response plays more prominent
roles during the late phase of infection and in recall challenges. In
support, TH17 cell recall responses are required for effective
clearance of Candida and K. pneumoniae infection [102,103]. TH17
responses have also been shown to be required for vaccine-induced
protection to the endemic fungal pathogens Coccidioides posadasii,
Histoplasma capsulatum, and Blastomyces dermatitidis [104] as well as a
number of other mucosa-associated pathogens [105].
As outlined above, host defences against intracellular pathogens
are classically considered to be coordinated by the TH1 domain.
However, recent data have also revealed a potential role for TH17
cells in the context of intracellular microbial infection [106].
Pulmonary infection of mice with the intracellular bacterium
Francisella tularensis induced a protective TH17 response [107,108],
and deletion of the IL-23/IL-17A axis, but not IL-17F or IL-22,
increased susceptibility to pulmonary tularemia [108]. Interest-
ingly, the reported biological function of IL-17A in this model was
induction of IL-12 and IFN-c production from APCs, subse-
quently promoting antigen-specific TH1 responses [108]. The
ability of IL-17A to regulate TH1 responses in the context of
microbial infections is not limited to the tularemia model, with
reports that IL-17 can influence adaptive immunity to pulmonary
Chlamydia muridarum [109] and Mycobacterium bovis BCG [110]
infection via similar mechanisms. However, impaired TH17-
mediated neutrophil recruitment is also likely to contribute to
these observed phenotypes [108]. Indeed, IL-23/TH17-dependent
neutrophil responses are important components of protective
immunity to other intracellular bacteria infections such as
Mycoplasma pneumonia [111] and Salmonella enterica serotype
Typhimurium [112,113]. Taken together, these studies suggest
that TH17 cells function in concert with TH1 cells to efficiently
resolve some intracellular bacterial infections. The molecular and
cellular basis of how these pathogens elicit TH17 cell responses
despite induction of a priming environment dominated by TH1-
polarising cytokines that antagonize TH17 differentiation remains
to be determined. Owing to inherent differences in PRR
stimulation by various bacteria, it is possible that certain bacteria
effectively induce potent IL-12/IFN-c responses, whilst other
bacterial pathogens require an additional IL-17-dependent mech-
anism for host IL-12/IFN-c production to resolve intracellular
infection. Moreover, the requirement of neutrophil responses to
intracellular infection poses something of a paradox, as these cells
are not thought to elicit robust effector responses against
intracellular pathogens. However, it may be that TH17-driven
neutrophil responses in these settings are active against the
extracellular phase of a pathogen’s life cycle, i.e., trans-epithelial
bacterial entry.
Virus-specific IL-17-producing CD4+ T cells have also been
detected in mice following herpes simplex virus (HSV) [114],
Theiler’s murine encephalomyelitis virus (TEMV) [115], and
vaccinia virus (VV) [116] infection, among others [20], albeit at a
lower magnitude than the prototypical antiviral TH1 response. In
these settings, TH17 responses appear to be detrimental to the host
as IL-17R-deficiency, or neutralisation of IL-17A, reduced HSV-
induced stromal keratitis [114]. Furthermore, neutralisation of IL-
17 during chronic TEMV infection increased viral clearance and
enhanced cytotoxic T cell responses [115], and neutralisation of
IL-17 during VV infection decreased the size of primary and
satellite lesions, and promoted viral clearance [116]. Nevertheless,
protective roles have also been ascribed to TH17-derived cytokines
in some viral infections [117]. This precarious balance of
protective versus harmful effector functions of TH17 cells has also
been observed in the context of parasitic infections where IL-17
has been shown to promote host defence against intestinal
Toxoplasma gondii infection at the expense of heightened immuno-
pathology [118] and contribute to control of S. mansoni infection in
the lung [119], yet enhance immunopathology associated with
schistosomiasis when mice are infected with S. mansoni in the liver
[120,121].
Thus, it is apparent that the TH17 subset is predominantly
associated with host defence against extracellular pathogens via
IL-17-mediated mobilisation of neutrophil responses. TH17 cells
may also serve as an important adjunct to TH1 responses in certain
intracellular infections by inducing neutrophil responses that may
function during the extracellular life cycle of intracellular
pathogens, or by influencing APCs to promote TH1 polarisation
in some intracellular bacterial infections that fail to induce efficient
pathogen-specific TH1 cell differentiation. Conversely, the TH17
response can be detrimental to the host in that it can contribute to
viral persistence and promote pathological inflammation associat-
ed with parasitic infection, which thereby presents these cells as a
potential therapeutic target to limit pathology in these settings.
Given that optimal immunity to extracellular infections is highly
dependent on the function of antibodies, the critical importance of
generating pathogen-specific memory TH17 cells in vaccine
development under conditions where a primary live infection
elicits protective TH17 cell responses is often overlooked. Further
study of this system will facilitate design of vaccines that result in
improved memory TH17 cell development in synergy with robust
antibody responses such that both humoral and cell-mediated
arms of the immune system enter into immunological memory.
Such strategies are indeed currently under development as is
evident by promising vaccine candidates that elicit pathogen-
specific TH17 cells in the context of anti–S. pneumoniae immunity
[122].
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T Helper 22 (TH22)
Recently, a subset of human TH cells dedicated to production of
the cytokine IL-22 has been described and proposed to be a
separate lineage of TH cell, designated TH22 [123,124]. IL-22 is a
pro-inflammatory member of the IL-10 family of cytokines that
appears to be particularly important for driving inflammatory
responses at cutaneous and mucosal surfaces [125]. TH22
differentiation from naı¨ve precursors has been reported to be IL-
6– and TNF-a-dependent [123] (Figure 1) and studies suggest that
IL-22 production by these cells is transcriptionally regulated by the
ligand-activated transcription factor aryl-hydrocarbon receptor
(AhR) [123,124,126,127] (Figure 1). Expression of the IL-22
receptor is restricted to stromal cells of the skin, intestine, liver,
kidney, pancreas, and lung [128,129], implicating TH22 cells as an
important mediator of the interaction of the immune system with
the non-hematopoietic environment. TH22 cells have been shown
to express the chemokine receptors CCR4, CCR6, and CCR10
[123,124], the ligands of which are known to regulate homing to
these organs.
In mice, IL-22 elicited from TH cells appears to be restricted to
the TH17 cell subset [130], with very few studies having detected
bona fide IL-17A2 TH22 cells in vivo. For this reason, evaluating the
function of this potential novel human T cell subset using murine
models of microbial infections currently presents significant
challenges. The TH22 response clearly shares many similar
features with the TH17 response, as evidenced by the lack of
obvious divergence between these responses in mice, and the
common reliance on AhR signalling for aspects of their function
[126]. Akin to the function of other TH17-derived cytokines, IL-22
ligation with its receptor markedly induces expression of multiple
antimicrobial peptides including the S100 proteins S100A7–A9, b-
defensins, the intestinal antimicrobial peptides RegIII-b and -c,
and stimulates production of protective mucus elicited from goblet
cells (Figure 2, panel A) [129–132]. IL-22 also upregulates
expression of the inflammatory chemokines CXCL1, CXCL2,
and CXCL5, which act in synergy with IL-17 to induce a
chemotactic environment that promotes neutrophilia at sites of
infection [133]. In addition to its antimicrobial and pro-
inflammatory effects, IL-22 also plays an important role in tissue
regeneration and wound healing by promoting epithelial cell
proliferation and inducing expression of anti-apoptotic proteins
[134].
IL-22 appears to play a dichotomous role in host defence
depending on the nature of the pathogen and site of infection.
Protective functions of IL-22 have been described in the context
of extracellular pathogen infection of the lung and intestine
including K. pneumoniae and C. rodentium. In most cases, IL-22 was
essential for control of bacterial replication and dissemination,
most likely in part due to the ability of this cytokine to potently
induce antimicrobial peptide production by epithelial cells at
these barrier surfaces [132,133]. In line with the protective role
for TH17 responses in antifungal immunity, IL-22-producing
CD4+ T cells have also been detected within the Candida-specific
memory T cell pool of healthy patients [135], and are defective in
patients with chronic mucocutaneous candidiasis [89,136,137].
However, the function of IL-22 in experimental C. albicans
infection remains controversial [98,138]. In a murine model of
oropharyngeal candidiasis, host defence was predominantly
mediated by IL-17, not IL-22 [96], whilst protective immunity
to C. albicans infected intragastrically was dependent on IL-22-
mediated production of antimicrobial peptides including S100A8
and S100A9, which prevented yeast dissemination to the kidneys
and stomach [139].
Numerous studies have suggested that immunity to intracellular
pathogens or parasites does not appear to rely on IL-22. Host
defence against the intracellular pathogens Mycobacterium avium and
L. monocytogenes, or the parasitic pathogen S. mansoni, is IL-22-
independent [140–142]. Unlike K. pneumoniae and C. rodentium,
these pathogens are not intimately associated with mucosal or
cutaneous barriers, which may underlie the redundant role of IL-
22 in these settings. Furthermore, IL-22 has been shown to be
detrimental in a murine model of oral T. gondii infection [140,143].
In this model, IL-23 promoted development of ileitis in an IL-22-
dependent manner. Whilst no difference in protozoan burden was
documented between WT and IL-22-deficient mice, WT mice
succumbed to infection due to intestinal necrosis, whereas IL-22-
deficient mice displayed increased survival rates with only minor
inflammation evident. Flow cytometric analyses implicated CD4+
T cells in the lamina propria as the major source of IL-22, which
contributed to T. gondii–induced panileitis principally via an
immune response directed against gut microbiota rather than the
protozoan pathogen. These data suggest that particular microbial
agents can induce detrimental IL-22-mediated pathogenic inflam-
mation [143]. On the contrary, studies have implicated protective
roles for IL-22 in certain intracellular pathogen infections
including experimental influenza and dengue infectious models
[144–146]. Despite reports that IL-22 deficiency or neutralisation
does not alter the outcome of M. tuberculosis infection in mice
[140,147], Scriba et al. demonstrated that a substantial proportion
of mycobacteria-specific TH cells from healthy M. tuberculosis–
exposed individuals produce IL-22 and are distinct from TH17
and TH1 cells, implicating IL-22 as an important cytokine axis in
human anti-mycobacterial immunity [148]. These reported
differences between mice and men in M. tuberculosis infection
support the notion that CD4+-T-cell-derived IL-22 plays a more
prominent role in the human than murine immune system, at least
under certain circumstances.
Despite the fact that TH22 cells are not clearly distinguishable
from the TH17 subset in mice, experiments to specifically evaluate
the significance of T-cell-derived IL-22 in models of microbial
infection have been performed. TH22 cells have been detected in
experimental coxsackievirus-B3-induced myocarditis where they
appear to exacerbate acute viral-induced myocarditis associated
with increased cardiac viral replication, heightened cardiomyop-
athy, and reduced survival rates [149]. More recently, a study by
Basu et al. demonstrated, for the first time, the function and
protective efficacy of TH22-derived IL-22 in the context of
microbial infection [150]. Significant expansion of IL-22-produc-
ing CD4+ TH cells that lacked expression of IL-17A occurred in
the colonic lamina propria during the late phase of C. rodentium
infection, implicating TH22 cells as the predominate TH subset
mediating host protection to this enteropathogenic bacterium.
Infection of IL-6-deficient mice led to profound defects in lamina-
propria-resident TH22 cell numbers, but not IL-22 production
from other cells, relative to IL-23-deficient mice or WT
counterparts, illustrating the importance of IL-6 in regulating
TH22 differentiation. The importance of T-cell-derived IL-22 in
protective immunity to this pathogen was reflected in the marked
decline in survival of mice treated with neutralising antibodies to
IL-22 administered after the peak of the innate immune response.
Moreover, adoptive transfer of in vitro–generated TH22 cells, but
not in vitro–generated TH17 cells, into Il22
2/2 mice rescued
recipient mice from pathogenic inflammation [150]. These
experiments are the first to definitively demonstrate the existence
and function of TH22 cells during enteropathogenic bacterial
infection. Further detailed studies are required to explore the
function of TH-cell-derived IL-22 in other infectious models.
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It is important to appreciate that, similar to other TH-cell-
derived cytokines, IL-22 production is not restricted to the CD4+
T cell compartment. Various other cells, including cd-T, NKT,
and CD8+, have the ability to produce IL-22 that participates in
host defence against microbes [70,132,139,142]. More specifically,
ILC3s have been shown to be a dominant innate source of IL-22
during infection [125]. Thus, in order to delineate the function of
TH22-derived IL-22 in the context of microbial infection, mice
with T-cell-specific deletions of IL-22 will be required. However,
to our knowledge, these reagents have yet to be developed.
Given the recent discovery of the TH22 subset, limited studies
have been carried out to date regarding the function of TH22 cells
in host defence to microbes. As discussed above, current data
suggest that the TH22 subset, in most cases, has overlapping
functions with the TH17 lineage in mice, in contrast to the human
system where IL-22-secreting T cells potentially form a distinct
lineage. It is now important to dissect how and why certain
infections elicit IL-22 responses that are favoured over IL-17-
mediated immunity in humans. The results of such studies may
provide crucial insights into how the balance of TH22/TH17 cells
defends against certain pathogens and may lead to the develop-
ment of vaccines tailored to particular microbial threats.
T Helper 9 (TH9)
IL-9 represents one of the most understudied cytokines in the
field of TH cell biology despite its diverse biological effects on
numerous cell types of myeloid, lymphoid, and stromal origin
[151]. IL-9 was first associated with TH2-mediated responses
following reports that IL-9 expression in T cells was high in TH2-
prone BALB/c mice relative to the TH1-prone C57Bl/6 mouse
strain during the course of L. major infection [152]. Subsequent
studies implicated a protective role for IL-9 in TH2-driven
responses during murine parasitic infections [153,154], with IL-9
levels in mesenteric lymph nodes correlating with expansion of
TH2 cell populations and a requirement of IL-9 for CSR to the
‘‘type-2’’ antibody isotypes IgG1 and IgE [155,156]. Furthermore,
an in vivo requirement for IL-4, a crucial mediator of TH2
differentiation, for induction of IL-9 expression by T cells was later
demonstrated in L. major–infected BALB/c mice [152]. The results
of these studies led to the classification of IL-9 as a TH2-derived
pro-inflammatory cytokine. However, despite the clear association
between IL-9 and TH2 responses, recent reports of high-level IL-9
production in macrophage– and neutrophil-dominated inflamma-
tory settings were counter to previous conceptions that IL-9 was
elicited from TH2 cells [157]. These findings have recently been
reconciled with the discovery that naı¨ve T cell priming in the
presence of IL-4 and TGF-b drives differentiation of a functionally
disparate subset of IL-9-secreting TH cells, designated TH9
(Figure 1) [158,159]. Subsequent studies have called into question
the requirement of IL-4 in TH9 differentiation with reports that
IL-4R signalling induces expression of suppressor of cytokine
signalling (SOCS) family member cytokine-induced SH-2 protein
(CIS), which inhibits STAT5/STAT6 signalling and subsequent
TH9 cell differentiation [160]. Indeed, IL-9 production in T cells
has been shown to be independent of IL-4 when activated in the
presence of TGF-b1 and IL-1a [161]. In vivo, the molecular
requirements for TH9 cell induction may involve many additional
stimuli including IL-25, TSLP, 1,25-dihydroxyvitamin D3, pro-
grammed cell death ligand (PD-L) 2, cyclooxygenase (COX)-2,
and tumor necrosis factor receptor superfamily member 4 (OX40)
[162]. Furthermore, data suggesting that the TH9 programme is
unstable and highly prone to plasticity have raised questions as to
whether this IL-9-secreting CD4+ T cell indeed represents a
distinct differentiation lineage. These aspects of TH9 cell biology
will not be discussed in this review but have been recently reviewed
elsewhere [162,163]. Differentiation of this subset is thought to
require the transcription factors PU.1, IRF4, and BATF [164–
166]. We have recently examined chemokine receptor expression
by TH9 cells and have shown that these cells express a broad range
of trafficking receptors, including CCR3, CCR6, and CXCR3
[167]. Notably, these receptors are also characteristically ex-
pressed by other TH cell subsets (TH2, TH17, and TH1,
respectively) suggesting that TH9 cells have the capability of being
recruited to, and contributing to multiple, functionally distinct
forms of inflammatory lesions. Whilst CCR4 expression by TH9
cells generated in our models was not detected, recent work has
suggested that these cells also express CCR4 and CCR8, which
would presumably allow these cells to traffic to cutaneous sites of
inflammation [166].
Given that the description of this new TH cell subset came years
after initial studies into the role of IL-9 in the context of microbial
infections were carried out, the function of IL-9 in protective
immunity will be discussed with conjecture on the role of bona fide
TH9 cells in these settings. Studies using IL-9 transgenic (IL-9
Tg)
mice have emphasized the importance of this cytokine in the
control of certain intestinal parasitic infections (summarized in
Figure 2, panel B). Following infection with Trichinella spiralis or T.
muris, IL-9Tg mice developed enhanced intestinal mastocytosis and
augmented pathogen-specific IgG1 responses, which led to rapid
parasitic expulsion from the gut [153,154]. Furthermore, treat-
ment of mice with neutralising antibodies to IL-9 during the
course of T. muris infection diminished immunity to this pathogen
[168]. In line with the protective phenotypes observed in IL-9Tg
mice, a specific role for TH9-derived IL-9 in protective immunity
to intestinal nematode infection was more recently assessed using
mice in which TGF-b signalling, a crucial mediator of TH9
differentiation, was specifically deleted in the CD4+ T cell
compartment. Infection of these mice with T. muris augmented
worm burden and reduced IL-9 but not IL-13 production in
mesenteric lymph nodes [159]. In these models, IL-9 appears to
predominantly function via activation of mast cells, the inflam-
matory mediators from which promote seminal processes required
for effective parasite expulsion such as induction of eosinophilia,
increased intestinal permeability and contractility, and mucus
production. Recent work by Licona-Limon et al. using novel IL-9
reporter mice (termed Interleukin Nine Fluorescent Reporter:
INFER) and newly generated IL-9-deficient mice on a BALB/c
background has revealed a critical and nonredundant role for TH9
and IL-9 in host defence to N. brasiliensis [169]. GFP reporter
activity was detected in CD4+ T cells and type-2 ILCs (ILC2: a
known prominent source of IL-9 in numerous type-2 models) in
both lungs and mediastinal lymph nodes during the course of N.
brasiliensis infection. IL-9-GFP detection in CD4+ T cells in the
lung peaked early and declined during the course of infection,
whilst IL-9-GFP+ ILC2s were detectable early and remained
present throughout, suggesting a transient window of CD4+-T-
cell-derived IL-9 in this model. Adoptive transfer of TH9 cells into
IL-9-deficient mice led to enhanced worm expulsion, demonstrat-
ing that TH9-derived IL-9 was an important contributor to IL-9-
dependent immunity in this model. The results of this study also
elucidated numerous other unknown aspects of TH9 cell biology
including the demonstration of functional differences between
TH2 and TH9 cells in host protection, despite prior reports
concluding that the function of these two subsets in other models
substantially overlapped. Surprisingly, transferred TH9 cells, but
not TH2 cells, into infected Rag2-deficient hosts decreased worm
burden. TH9-mediated protection correlated with increased
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numbers of mast cells and basophils in lungs and spleens of
infected mice, implicating these innate effector cells as the key
responding cell types to IL-9-mediated immunity. Moreover,
recent findings by Turner et al., using IL-9 fate mapper reporter
mice (termed IL-9CreR26ReYFP mice, which permanently label
cells with enhanced YFP (eYFP) that have expressed IL-9
irrespective of their current IL-9 expression status) and IL-9R-
deficient animals, support the notion that IL-9 plays a critical role
in host defence against N. brasiliensis infection [170]. Both eYFP+
CD4+ T cells and ILC2 cells were detected in the lung during
infection. IL-9 in this setting was demonstrated to positively
regulate IL-5 and IL-13 responses, likely ILC2-derived IL-5 and
IL-13 as TH2 cell numbers were unchanged in IL-9R-deficient
animals, promote ILC2 cell survival, drive lung tissue repair
mechanisms, and promote eosinophil recruitment and alternative
activation of macrophages. These studies highlight the critical
importance of both TH9 and ILC2-derived IL-9 in host defence to
N. brasiliensis. However, the results of these studies are not in
keeping with a prior study, which demonstrated that IL-9-deficient
mice on a mixed genetic background (1296C57Bl/6 (F2))
effectively control infection with N. brasiliensis [171]. The
conflicting results of these studies warrant further investigation of
IL-9 function in anti–N. brasiliensis immunity but suggest that the
overall importance of IL-9 depends on complex multi-genetic
factors. IL-9 deficiency, using 1296C57Bl/6 (F2) Il9
2/2 mice
backcrossed six times onto a BALB/c background, led to modest
reductions in mast cell numbers but did not alter the outcome of
infection with the flagellated intestinal protozoan parasite Giardia
lamblia [172]. Moreover, IL-4 has been shown to control intestinal
parasitic infections in an IL-5/IL-9/IL-13 triple-knockout mouse
[173]. Collectively, these data suggest that the TH9 subset may
serve as an important adjunct to the TH2 response in certain
parasitic infections; however, it appears to be superfluous in
certain circumstances where TH2 responses suffice. In support, IL-
9 has been shown to precede and regulate TH2-associated cytokine
responses in certain parasitic infections [169,170]. Given that TH9
cells have been reported to produce the CCR4 ligands CCL17 and
CCL22 [164], and studies that demonstrate that IL-9 can induce
expression of the inflammatory chemokine CCL11 by smooth
muscle cells [174,175], early IL-9 responses may be important for
amplifying CCR3+ eosinophil [176] or CCR3+/CCR4+ TH2 cell
responses at sites of microbial infection.
The function of IL-9 in other microbial infections is less well-
defined with conflicting conclusions having been reached to date.
Following reports that bronchial secretions from infants with
respiratory syncitial virus (RSV) bronchiolitis contained high levels
of IL-9 [177], the function of IL-9 was specifically investigated in a
murine model of RSV vaccination and infection. Antibody-
mediated neutralisation of IL-9 in these models resulted in
enhanced viral clearance from the lungs and had varied effects
on pathology depending on the timing of IL-9 depletion [178]. In
contrast to the detrimental roles of IL-9 in the RSV model,
prophylactic administration of recombinant IL-9 into mice
infected with a lethal dose of Pseudomonas aeruginosa enhanced
survival via suppression of inflammatory cytokines including IFN-c
and TNF-a, and induction of the immunomodulatory cytokine IL-
10 [179]. Endogenous IL-9 induction was detected in spleens of
mice infected with sublethal, but not lethal, doses of P. aeruginosa;
however, the precise cellular source of this IL-9 was not explored
[179]. IL-9-secreting CD4+ T cells have also been detected in
humans with M. tuberculosis infection [180]; however, the
functional significance of these cells in immunity to this pathogen
has yet to be investigated. It is clear that a great deal of work is still
required to delineate the function of TH9 cells in the context of
microbial infections. Owing to the recent discovery of this subset,
the majority of studies investigating the function of IL-9 in
protective immunity have utilised systemic means of IL-9
blockade/neutralisation such as the use of antibody-mediated
neutralisation or IL-9-deficient mice. However, IL-9 can be
elicited from multiple cell types including ILCs, mast cells, Tregs,
and natural killer T cells [181]. Therefore, more refined studies
making use of the recently described INFER mice [169], which
will be useful to detect IL-9-expressing cells in real time, IL-9 fate-
mapping reporter mice [182], or mice with specific deletions of the
TH9-specific transcription factor PU.1 in the T cell compartment
[164] are required to determine which microbial infections elicit a
TH9 response and whether this response is protective.
Taken together, it appears that the TH9 response may play
significant roles in immunity to certain intestinal parasites and
contribute to host protection via amplification of the infectious
site’s chemotactic potential and mediating mast cell and basophil
activation. Although less well-understood, the TH9 response may
also participate in a diverse array of other infections; however, it
appears that these cells play a role supplementary to TH2 cells and
in some cases a potentially detrimental role in host defences.
T Follicular Helper (TFH)
The TH1, TH2, TH17, TH22, and TH9 subsets represent
populations of effector helper T cells that contribute to immune
responses at peripheral sites of infection. However, within
secondary lymphoid organs, populations of effector CD4+ T cells
interact with clonally selected B cells to produce humoral
immunity by providing crucial signals that regulate B-cell survival,
proliferation, affinity maturation, CSR, and differentiation into
memory B– or long-lived plasma cells. This molecular cross-talk
between B and T cells occurs in two waves: first at the T-B border
where CD4+-T-cell-derived cytokines instruct developing B cells to
switch to an appropriate isotype and actively form specialised
structures known as germinal centres (GC), followed by further
interactions within the GC that ultimately determine the quality of
antibody response generated [183]. Prior to 2004, CD4+ T cells
localised to GCs were thought to be a branch of canonically
derived TH1 or TH2 cells that migrated into B cell follicles to
coordinate CSR to IgG2A and IgG1 via IFN-c and IL-4,
respectively [184]. However, recent data have demonstrated that
these GC-localised T cells, now referred to as follicular TH cells
(TFH), are in fact a distinct differentiation lineage (Figure 1 and
Figure 3). These cells are characterised by expression of the
lineage-specific master regulator Bcl6 (the transcription factor c-
Maf is also crucial to this subset) [185–187], as well as the ability to
produce a range of cytokines including IL-4, IFN-c, IL-21, and IL-
17A [188–195] (Figure 1 and Figure 3). TFH cells are also
characterised by high expression of the chemokine receptor
CXCR5, which mediates migration into B cell follicles and GCs
that are rich in CXCL13 [196,197].
Current models of TFH cell development describe a ‘‘two-wave’’
theory of differentiation: DC-instructed commitment to the TFH
cell lineage (i.e., pre-TFH cell differentiation) followed by B-cell-
instructed consolidation of the TFH cell programme (i.e., GC-
resident TFH cells) [198]. It is thought that TFH cells selectively
differentiate from naı¨ve precursors with the highest affinity to any
given antigen [199], consistent with reports that the magnitude of
TFH cell generation is dependent on the dose of Ag made available
to the T cell during its interaction with a DC [200]. STAT3
activation downstream of IL-6 and/or IL-21 has also been shown
to promote early commitment to the TFH cell lineage via induction
of their master transcriptional regulator Bcl6 [193,201,202].
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Interestingly, STAT1 and STAT4 activation downstream of IL-6
and IL-12 signalling respectively, two transcription factors known
to promote TH1 cell differentiation, have been shown to induce
expression of Bcl6 in CD4+ T cells [203–206]. Nakayamada et al.
provided evidence that TH1 cell differentiation may occur through
a TFH-cell-like transitional state where T-bet and Bcl6 are co-
expressed in the same cell [207]. T-bet was shown to eventually
outcompete Bcl6 function when IL-12 signalling persists leading to
downregulation of Bcl6, and TH1 lineage fate commitment then
predominating [207]. Thus, the earliest events of DC-instructed
commitment to the TFH cell lineage are complex and likely involve
the integration of numerous microenvironmental signals [208].
Importantly, differentiation of TFH cells appears to be independent
of the other known effector subsets as mice deficient in genes
critical to TH1, TH2, and TH17 lineage development do not
display marked differences in TFH cell induction [193]. Early TFH
cell commitment is coupled with the downregulation of CCR7 (the
ligands of which are in highest concentration in T cell zones of
SLOs) and upregulation of CXCR5 (the ligands of which are in
highest concentration in the B cell zones), facilitating the
movement of the pre-TFH cell to the T-B border [209]. Stable
interactions with cognate B cells at this border are required for the
terminal differentiation of the TFH cell programme and are
coupled with further upregulation of Bcl6, thus promoting
expression of genes required for B cell help, and CXCR5, which
facilitates the migration of these cells deeper into the B cell zone
and into GCs where they execute their predominant effector
function [198,210].
Given that the ability of the host to generate high-affinity
neutralising/opsonising antibody responses via the GC reaction is
seminal for defence against a number of ever-evolving pathogens,
the function of TFH cells is predominantly associated with
regulating the process of antibody affinity maturation through
governance of selection, survival, proliferation, and differentiation
of high-affinity, pathogen-specific B cell clones. TFH cells execute
these effector functions via the wealth of cell-surface and soluble
proteins that they express (reviewed in [184]) including CD40L,
which interacts with GC-B-cell-expressed CD40 and imprints an
anti-apoptotic transcriptome in the responding B cell [211,212],
and IL-21, which promotes the proliferation of GC B cells
[190,213,214] and drives their differentiation toward the plasma
cell compartment in both mice [215] and humans [216–218].
Therefore, it is perhaps of no surprise that individuals with
mutations in these factors exhibit defects in generating isotype-
switched high-affinity antibody responses and, thus, are more
prone to opportunistic infection. For instance, patients with
Figure 3. Mechanism of action of TFH cells. TFH cells are effector TH cells that govern the quality and magnitude of an antibody response via
regulation of B cell selection, differentiation, proliferation, and class switch recombination. TFH cells execute these effector functions via expression of
various cell surface proteins and cytokines (including IL-21). They are generated during antigen presentation in the T cell areas of secondary lymphoid
organs in the presence of IL-21 and IL-6, which is thought to upregulate their master transcription factor Bcl6 (pre-TFH), after which they migrate to
the T:B border where interaction with cognate B cells regulates a number of processes including promoting survival of recently activated B cells,
regulating the fate decision of a B cell down extrafollicular plasmablast or germinal center (GC) B cell differentiation pathways, and induction of class
switch recombination in GC B cells. Stable interactions with cognate B cells at this border also consolidate the TFH cell programme (pre-TFH to TFH cell
differentiation) with further upregulation of Bcl6 and entry into developing GCs. Within GCs, TFH cells are crucial for the regulation of affinity
maturation, development of memory B cell populations, and high-affinity antibody responses via regulation of long-lived plasma cell differentiation.
doi:10.1371/journal.ppat.1003905.g003
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mutations in Cd40lg develop the primary immunodeficiency hyper-
immunoglobulin M syndrome, characterised by a severe deficit in
GC development and lack of circulating isotype-switched immu-
noglobulin, and, subsequently, an increase in susceptibility to
recurrent bacterial infections and are unresponsive to vaccination
[214,219,220]. Similarly, patients with a mutation in the SLAM-
associated protein (SAP) encoding gene Sh2d1a, a signalling
protein expressed by TFH cells critically required for the formation
of stable T:B conjugates [221,222] and GC-TFH cell expression of
IL-4 [223], develop X-linked lymphoproliferative (XLP) disease
characterised by an increased susceptibility to a number of
pathogens (particularly Epstein-Barr virus infection, which can be
fatal in children) due to abortive B cell responses [224].
Central to the ability of the host to generate an effective
antibody response to a given pathogen is the decision of B cells to
class switch to an appropriate antibody isotype for maximum
effector function tailored to the nature of the microbe. CSR to
IgG2A is driven by IFN-c and plays a vital role in the neutralisation
of viruses, complement fixation, and opsonisation of microbes via
the Fc portion. Conversely, IL-4-mediated CSR to IgG1 and IgE is
essential for antibody-mediated cell cytotoxicity mechanisms in the
context of antiparasitic immunity. Despite the clear demonstration
by multiple groups that differentiation of Bcl6+ TFH cells in vivo is
independent of TH1, TH2, or TH17 differentiation pathways
[185–187], how TFH cells could coordinate CSR during particular
infections via IL-4 and/or IFN-c posed something of a paradox.
Using reporter systems and other elegant approaches, recent work
has revealed that TFH cells can differentiate in a variety of priming
environments and that the cytokine milieu present during T cell
activation likely favours the production of IFN-c or IL-4 by TFH
cells in the context of TH1– or TH2-polarising infections,
respectively (Figure 3). Using 4get/KN2 dual reporter mice,
which faithfully report cells that have actively transcribed from the
Il4 locus and cells actively producing IL-4 [225], Reinhardt and
colleagues demonstrated that during infection with the type-2
pathogens L. major or N. brasilienis, IL-4 production in draining
lymph nodes was restricted to bona fide TFH cells that were
phenotypically and functionally distinct from canonical TH2 cells
[226]. TFH-cell-derived IL-4 was important for driving parasite-
specific IgG1 responses as GC B cells sorted from IL-4-producing
TFH:GC B cell conjugates were actively undergoing CSR to IgG1
[226]. Using IFN-c reporter mice, the same study demonstrated
that GC B cells sorted from IFN-c-producing TFH:GC B cell
conjugates were actively undergoing CSR to IgG2A [226].
Consistent with these observations, Lutjhe and colleagues recently
demonstrated that TFH cells favoured the production of IFN-c
following influenza infection [227]. However, development of
IgG2C
+ (C57Bl/6 mouse equivalent of IgG2A) GC B cells was
unperturbed in chimeric mice reconstituted with IFN-c-deficient
CD4+ T cells [227]. Collectively, the results of these studies suggest
that TFH-derived IL-4 is seminal for generation of pathogen-
specific IgG1 antibody responses whilst TFH-derived IFN-c is not
essential for an IgG2A antibody response, although it may play a
supplementary role in this process.
Much controversy still exists in the field of TFH cell biology
regarding the origin of these cells during pathogen encounter.
Although it is apparent that the differentiation programmes of T
helper cells with B-cell helper function are separate to other
effector TH cell subsets as described above, studies have
demonstrated that non-TFH effector T cells can re-differentiate
to the TFH lineage [228,229] (Figure 3). TFH cells have been
described to arise from TH1 in the context of LCMV infection
[230]; from TH2 cells in the context of Heligmosomoides polygyrus, S.
mansoni, and N. brasiliensis infection [188,226,229]; and from TH17
cells in the Peyer’s patches, which was shown to be critical for
antigen-specific IgA responses [231]. From a clinical perspective,
the ability of the host to generate high-quality antibody responses
governs the success of most currently available vaccination
strategies; therefore, understanding the differentiation pathways
and cytokine-secreting repertoires of TFH cells under different
immunising conditions is imperative to the design of vaccines that
generate high-affinity antibody responses with the appropriate
dominant antibody isotype tailored to the nature of the microbe of
interest. The recent development of cytokine fate-mapping
reporter mice and generation of Bcl6 and IL-21 reporter mice
that faithfully map TFH cells during an immune response
[227,228] should facilitate the collection of important information
regarding these processes.
Concluding Remarks
The adaptive immune response has a broad array of strategies
to combat infectious, potentially pathogenic agents. One of the
most important strategies utilised is to tailor the immune response
to combat particular classes of microbial agents, and TH cell
subsets play a crucial role in this process. Significant progress has
dramatically improved our understanding of TH cell biology with
a number of new subsets recently being identified and discussed in
this review, as well as emerging effector TH cell phenotypes, such
as granzyme B-expressing cytolytic CD4+ T cells found in certain
viral infections [232] and subsets of TH cells dedicated to
production of IL-21 (TH21) [233], that have not yet been shown
to be a distinct effector lineage and are not discussed here but
warrant further study. Together, these cells give the adaptive
immune response the potential to deliver antigen-specific inflam-
matory responses that instruct and complement pathogen-tailored
innate inflammatory responses. These TH responses differentially
combat extracellular pathogens, enhance cell-mediated immunity
required to combat intracellular pathogens, and promote humoral
immunity to produce antibodies that target pathogens. Future
challenges include further dissection of this system to identify other
potentially important subsets and identifying ways in which to
utilise this knowledge to develop better strategies to combat
infectious pathogens. Ascertaining such knowledge will be crucial
for determining whether future vaccination strategies: i) elicit
robust TFH cell responses with the appropriate cytokine-secreting
repertoire to induce an antibody response tailored to the nature of
the pathogen; and ii) activate the appropriate components of the
innate immune system that induce a priming microenvironment
driving differentiation of the desired pathogen specific-effector TH
cell subset and/or -CTL activation such that upon contact with
the live pathogen, all aspects of the adaptive immune system are
armed to promote effective, pathogen-tailored clearance of the
infectious agent. Thus, increased understanding of the complex
dynamics of TH differentiation in the context of microbial
infections should lead to improved vaccine efficacy for a wide
range of human pathogens.
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